DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has been selected by a subsidiary of a U.S.-based Fortune 500 technology and engineering company to provide its digital therapeutics solution to eligible employees. DarioHealth’s partnership with Vitality Group made this agreement possible, which is DarioHealth’s first client in the self-insured employer market. One of the largest wellness companies in the world, Vitality Group blends industry-leading smart tech, data, incentives and behavioral science to inspire healthy changes in individuals and their organizations; an estimated 20 million people in 26 markets engage in the Vitality program. Under the announced agreement, members of the Fortune 500 subsidiary are expected to begin enrollment this month; those members will be eligible to receive Dario’s diabetes and hypertension solution. “We are very pleased that our digital therapeutic solution has been selected by one of Vitality Group’s clients,” said DarioHealth president and general manager Rick Anderson in the press release. “We believe that this represents another employer that recognizes the benefits of our industry-leading chronic condition solutions, high level of member satisfaction, ease of integration and commitment to transparent approach to only charging for engaged members. We look forward to working with them to assist their members living with diabetes and hypertension to improve their health and thereby reducing the cost of care.”
To view the full press release, visit https://ibn.fm/TB6LE
About DarioHealth Corp.
DarioHealth is a leading global, digital-therapeutics company revolutionizing how people with chronic conditions manage their health. By delivering evidence-based interventions driven by connected devices, data, high-quality software and coaching, the company makes the right thing to do the easy thing to do. The company’s cross-functional team operates at the intersection of life sciences, behavioral science and software technology. Dario offers one of the highest-rated diabetes and hypertension solutions on the market; its highly engaging, user-centric MyDario(TM) mobile app is used regularly by tens of thousands of consumers worldwide. The company is rapidly expanding into new chronic conditions and geographic markets, using a performance-based approach to improve its users’ health. For more information about the company, please visit www.DarioHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork